Our mission is to create gap-filling animal vaccines and biotherapeutics using TVG’s herpesvirus delivery platform 

Animal vaccines and biotherapeutics delivery platform

TVG is using recombinant viral vector technology to develop new animal vaccines and biotherapeutics for use in livestock and companion animals:

  • Diseases caused by agents such as Streptococcus suis, bovine tuberculosis, porcine reproductive & respiratory syndrome, porcine circovirus, bovine respiratory syncytial virus, lumpy skin disease, ovine enzootic abortion and African swine fever which have a high impact on production of economically important livestock;
  • Diseases caused by agents such as leishmaniasis, equine influenza and feline immunodeficiency;
  • Diseases of ageing and chronic health conditions in pet animals.
Virus background
Piglet being held whilst waiting for vaccination

Our Pipeline

We are creating vaccine delivery platforms for viral and bacterial pathogens to address a growing number of diseases in animals:

Streptococcus suis
• Porcine reproductive and respiratory syndrome (PRRS)
• Porcine circovirus-2
• Porcine cysticercosis
• Bovine tuberculosis
• Bovine bacterial mastitis
• Bovine respiratory syncytial virus
• African swine fever 
• Lumpy skin disease
• Ovine enzootic abortion
• Canine leishmaniasis
• Feline immunodeficiency virus
• Equine influenza virus
• Canine oncology

Leadership Team

Jeremy_Profile_TVG

Jeremy Salt, PhD

CEO

Michael Jarvis, PhD

Founder & CSO

Matthew White Profile

Matthew White

Director

Prof. Robert Fern

Director

Latest News

Partners